IDEAYA Biosciences, Inc. $IDYA Stake Lifted by Tema ETFs LLC

Posted by on Aug 13th, 2026

Tema ETFs LLC boosted its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Free Report) by 21.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 135,847 shares of the company’s stock after buying an additional 23,538 shares during the period. Tema ETFs LLC owned 0.15% of IDEAYA Biosciences worth $5,063,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in IDYA. Farther Finance Advisors LLC boosted its holdings in shares of IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the period. ANTIPODES PARTNERS Ltd increased its holdings in shares of IDEAYA Biosciences by 49.4% in the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock worth $40,000 after acquiring an additional 380 shares during the period. Global Retirement Partners LLC bought a new stake in IDEAYA Biosciences in the 4th quarter valued at about $61,000. Daiwa Securities Group Inc. lifted its position in IDEAYA Biosciences by 16.1% in the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock valued at $66,000 after purchasing an additional 436 shares during the last quarter. Finally, Fifth Third Bancorp acquired a new position in IDEAYA Biosciences during the 1st quarter valued at about $84,000. 98.29% of the stock is currently owned by institutional investors.

Insider Activity at IDEAYA Biosciences

In related news, CAO Briseno Andres Ruiz sold 9,550 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total transaction of $382,095.50. Following the sale, the chief accounting officer owned 26,466 shares of the company’s stock, valued at $1,058,904.66. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 4.70% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have commented on IDYA. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, June 2nd. Mizuho reduced their price objective on IDEAYA Biosciences from $52.00 to $50.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wedbush increased their price objective on IDEAYA Biosciences from $58.00 to $60.00 and gave the stock an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Friday, July 17th. Finally, Truist Financial lowered their target price on IDEAYA Biosciences from $63.00 to $59.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. Fourteen research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and an average price target of $50.12.

Check Out Our Latest Report on IDEAYA Biosciences

IDEAYA Biosciences Stock Up 0.3%

Shares of IDYA opened at $36.96 on Thursday. The firm has a market capitalization of $3.25 billion, a PE ratio of -19.05 and a beta of -0.10. The firm has a 50-day moving average price of $34.88 and a 200 day moving average price of $32.68. IDEAYA Biosciences, Inc. has a 52-week low of $23.23 and a 52-week high of $40.58.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.16). The company had revenue of $8.86 million for the quarter, compared to the consensus estimate of $8.02 million. IDEAYA Biosciences had a negative return on equity of 16.73% and a negative net margin of 75.93%.The firm’s quarterly revenue was up 8800.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.88) earnings per share. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -4.38 EPS for the current year.

IDEAYA Biosciences Profile

(Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.

Read More

Institutional Ownership by Quarter for IDEAYA Biosciences (NASDAQ:IDYA)

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.